Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Invested Capital (2016 - 2026)

Champions Oncology has reported Invested Capital over the past 16 years, most recently at $4.3 million for Q1 2026.

  • Quarterly results put Invested Capital at $4.3 million for Q1 2026, down 21.69% from a year ago — trailing twelve months through Jan 2026 was $4.3 million (down 21.69% YoY), and the annual figure for FY2025 was $3.8 million, up 298.21%.
  • Invested Capital for Q1 2026 was $4.3 million at Champions Oncology, up from $4.2 million in the prior quarter.
  • Over the last five years, Invested Capital for CSBR hit a ceiling of $9.2 million in Q1 2022 and a floor of -$2.1 million in Q1 2024.
  • Median Invested Capital over the past 5 years was $4.2 million (2025), compared with a mean of $4.0 million.
  • Biggest five-year swings in Invested Capital: tumbled 141.05% in 2024 and later soared 1165.66% in 2025.
  • Champions Oncology's Invested Capital stood at $9.2 million in 2022, then plummeted by 98.99% to $93000.0 in 2023, then soared by 632.26% to $681000.0 in 2024, then skyrocketed by 521.29% to $4.2 million in 2025, then rose by 1.23% to $4.3 million in 2026.
  • The last three reported values for Invested Capital were $4.3 million (Q1 2026), $4.2 million (Q4 2025), and $3.5 million (Q3 2025) per Business Quant data.